NCT05342636 2025-12-17A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)Merck Sharp & Dohme LLCPhase 1/2 Completed90 enrolled
NCT02564263 2023-03-13KEYNOTE-181Merck Sharp & Dohme LLCPhase 3 Completed628 enrolled 27 charts 1 FDA